MF59 adjuvant: the best insurance against influenza strain diversity. - Test2 - elhamkhani - TriplyDB

MF59 adjuvant: the best insurance against influenza strain diversity.

MF59 adjuvant: the best insurance against influenza strain diversity.

http://www.wikidata.org/entity/Q30402018

about

Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development B Cells and Functional Antibody Responses to Combat Influenza Hypothesis driven development of new adjuvants: short peptides as immunomodulators Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein A caprine herpesvirus 1 vaccine adjuvanted with MF59™ protects against vaginal infection and interferes with the establishment of latency in goats Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada Factors contributing to the immunogenicity of meningococcal conjugate vaccines Adjuvant efficacy of mOMV against avian influenza virus infection in mice.Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.Bringing influenza vaccines into the 21st century.Assessment of mOMV adjuvant efficacy in the pathogenic H1N1 influenza virus vaccine.Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults Controlling the HIV/AIDS epidemic: current status and global challenges Adjuvant solution for pandemic influenza vaccine production Altered response to A(H1N1)pnd09 vaccination in pregnant women: a single blinded randomized controlled trial A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein Aging impairs murine B cell differentiation and function in primary and secondary lymphoid tissues Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates.Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population.Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens Protective efficacy induced by recombinant Clostridium difficile toxin fragments Chlamydia vaccines: recent developments and the role of adjuvants in future formulations.Improving immunogenicity and effectiveness of influenza vaccine in older adults.Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants.Adjuvants for human vaccines.The gracefully aging immune system.Adjuvanted influenza vaccines.Inactivated influenza virus vaccines: the future of TIV and QIV.Overview of Vaccine Adjuvants: Introduction, History, and Current Status.A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines.Vaccines, reverse vaccinology, and bacterial pathogenesis.Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients.Terpene metabolic engineering via nuclear or chloroplast genomes profoundly and globally impacts off-target pathways through metabolite signalling.Identification of Biologically Active Pyrimido[5,4-b]indoles That Prolong NF-κB Activation without Intrinsic Activity.Emulsion based vaccine adjuvants.Vaccines for the twenty-first century society.

P2860

Q21284959-6CF1869F-EF4B-4A15-9A64-D757585094CE Q26801639-1F0DD1D0-A300-4938-81E8-7E4B0DFCD639 Q27023844-8DDAE774-4ABF-4353-B0B1-222D6C4FBBFB Q28730561-E7D84B0E-0E1C-4A48-894B-C373B51FE3F0 Q28730610-A710E39F-C161-4117-AB23-A20C2D1DAB63 Q28742771-E61AF2B1-78DA-4054-A6ED-1A681D75F847 Q28828544-0A12A58F-99E5-487E-BC74-05D00FCB26BA Q30219688-60EDF9C9-A1A3-49BB-9E43-A2BB5D8B8AC2 Q30223941-D0833899-4158-45B9-86B4-B9A2905CEE21 Q30352329-788E3037-6EDB-45D1-8C3F-6B029B5ADAED Q30357413-4DCECC8C-A235-452C-B023-83FD6699FDCD Q30364462-3D78AC39-D280-46AB-B688-B85BBAFBCFB5 Q30375872-2F607563-0031-4398-9B65-A65116DEFBCF Q30413670-8BB7820F-90F2-4A09-9AE0-D37396463457 Q30420558-3F91D4C1-104B-4A34-B8CB-EA50589E6841 Q30422038-6998F36C-5FB1-4371-A9EA-2EE38D55CA36 Q30430043-DDE6160B-C419-4FD1-BF0D-676081E9FE03 Q33578064-F808D2BA-8309-45C3-B71E-E7A584F1626F Q35004481-4F37650C-5A9A-4A27-B41F-E5149CCC37BB Q35806803-DE7421C7-852D-44A1-B372-EEF7E0CBFF9B Q35849215-1E787BA5-24E0-48E4-B53E-A70E6EDD0214 Q35874111-18286036-CBBE-4CAE-B381-ABFEC7BF80D7 Q36500269-DB40EE25-823A-4834-B931-3D977DB03189 Q37036112-7BA3D3FB-C2B0-4355-BDF3-2B36C285EE65 Q37849913-25906099-F325-4917-8D4F-B362C5936813 Q37951523-7D3E3D96-2A2D-434A-9CF2-69C96B35B922 Q37981769-203C4DFF-903A-405F-BE5C-0FFF03EC53DE Q38004229-DCA6CC96-B005-4CCC-9842-957B962240BA Q38107139-884363AE-934C-4726-8B72-5CBDA25E2159 Q38140045-C0EB07EE-D11B-4A98-83D2-77082F0F6EBC Q38683726-D9E76901-6A34-44DF-B367-A4CB85277E3C Q38813523-1996E69F-2829-465A-87B5-9A2755413F7C Q39373123-40BEF814-DAAB-42E5-A4DA-6E0F77016CDA Q39426398-17D7E775-ADA4-468E-B4AE-2445995E901E Q40116011-D7D807BF-A2EC-499A-9E97-3E2BCE392CAB Q40306881-41981B49-0974-469A-BA77-F55292DCFC50 Q41813163-BE13BB11-7DAB-4ADF-9B61-72E689890FDF Q46360938-5D98D447-CFE2-4535-8E33-1BBB11CB85E6 Q47105588-B380319B-C431-48BB-AE8A-1915AF8F53FA Q51664205-1EBF3285-40AF-433F-BFA6-52A4C4B28D98

P2860

MF59 adjuvant: the best insurance against influenza strain diversity.

http://www.wikidata.org/entity/Q30402018

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

MF59 adjuvant: the best insurance against influenza strain diversity.

@ast

MF59 adjuvant: the best insurance against influenza strain diversity.

@en

type

label

MF59 adjuvant: the best insurance against influenza strain diversity.

@ast

MF59 adjuvant: the best insurance against influenza strain diversity.

@en

prefLabel

MF59 adjuvant: the best insurance against influenza strain diversity.

@ast

MF59 adjuvant: the best insurance against influenza strain diversity.

@en

P1433

Q30402018-733AB351-BAE8-4EC6-B596-6C78F780D060

P1476

Q30402018-708F16B0-CDB7-48BA-B47F-E210033D2691

P2093

Q30402018-0E5E79CB-C64E-4D00-8653-AA68AF478EE8

Q30402018-71967B72-F98C-46B1-B9B9-3423612CC9B5

Q30402018-D834A883-61B6-45F2-8C79-2290542A19E5

Q30402018-DBFC8436-014E-4ECA-AB9C-5767FBC58176

P2860

Q30402018-0259FF0E-E175-4496-84CD-416F159BDDA9

Q30402018-058BEF56-379E-4E2B-865E-05C7465B3F9D

Q30402018-06A3A282-3F63-40D5-A785-D48E54342D04

Q30402018-092AE5D3-DC30-4268-A10C-72A98B9EF08F

Q30402018-09C42B24-A62D-436F-B2BB-B47610346272

Q30402018-0B6FF772-84EA-4A40-98CD-B456BE4A06C3

Q30402018-1356DB3D-18D6-47B3-B1D6-B117A8E735A0

Q30402018-13BCD629-0CFB-4447-B2F8-DD4992AFBE36

Q30402018-14C85EF8-0FF1-4DA4-891E-2B9BED3E7395

Q30402018-16328A64-6D58-4362-B410-EABDFF9DF87D

P304

Q30402018-48E85F58-CB3B-4CD5-ADFC-674A6EBA8E15

P31

Q30402018-3ED00E96-A013-488B-AC1B-F5517BE1AF81

P356

Q30402018-D2132274-80DF-4616-B972-FEE028D02B6C

P433

Q30402018-CAF4514D-DB8B-4D2A-AF61-D1EEF7BF46B1

P478

Q30402018-0F29D0B9-1B29-458E-B529-F35D372FE576

P50

Q30402018-CCE28215-47F2-4E20-B2B4-9805802BA506

P577

Q30402018-6024C9D6-1D31-4126-9A5E-0ABDC0274C69

P698

Q30402018-9A098B57-E081-4E93-A29E-A407C3458940

P356

P1433

Expert Review of Vaccines

P1476

MF59 adjuvant: the best insurance against influenza strain diversity.

@en

P2093

Derek T O'Hagan

http://www.w3.org/2001/XMLSchema#string

Ennio De Gregorio

http://www.w3.org/2001/XMLSchema#string

Giuseppe Del Giudice

http://www.w3.org/2001/XMLSchema#string

Theodore Tsai

http://www.w3.org/2001/XMLSchema#string

P2860

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

Antibody recognition of a highly conserved influenza virus epitope

Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene

Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans

Seasonal and pandemic influenza: a 2007 update on challenges and solutions.

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

P304

447-462

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERV.11.23

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21506643

http://www.w3.org/2001/XMLSchema#string